-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, under the influence of domestic pharmaceutical policies, drastic changes in the market and the rise of a large number of local innovative pharmaceutical companies, major pharmaceutical companies at home and abroad have begun to adjust their strategies and organizational structures in China on a large scale.
Tube flow is also significantly accelerated
.
Data shows that in 2021, more than 200 executives in the pharmaceutical industry will leave
.
In the first half of the year alone, a total of 128 executives in the pharmaceutical industry left
.
From the perspective of the overall personnel changes, the positions of vice president, general manager, deputy general manager, secretary of the board of directors, and financial director/director have changed a lot
.
It is worth noting that the current time has come to 2022.
Judging from the current industry trends, the changes of executives in the pharmaceutical industry are still further intensifying.
Recently, many domestic and foreign pharmaceutical companies have announced new changes in executives
.
For example, recently, Dong'e Ejiao has sent two news of personnel changes in a row.
Due to the change of work content, its chairman Han Yuewei and president Gao Dengfeng have resigned one after another
.
Among them, Mr.
Han Yuewei mainly applied for his resignation as chairman and director of the 10th board of directors of the company, and simultaneously resigned as chairman of the strategy committee of the 10th board of directors of the company
.
After resigning, he will no longer hold any positions in the company
.
Mr.
Gao Dengfeng will continue to serve as a director of the tenth board of directors of the company after applying for resignation as the company's president and legal representative
.
Prior to this, biopharmaceutical company Oculis SA also announced the appointment of Ding Weibo as global chief operating officer and general manager of China, effective February 1, 2022, based in Hong Kong, China
.
Before joining Oculis, he was President of Fresenius Kabi China
.
Before joining Fresenius Kabi, Ding Weibo worked at Novartis China for more than 10 years
.
In addition, he has held senior positions at Bristol-Myers Squibb and Xi'an Janssen
.
On January 6, Buchang Pharmaceutical announced that Liu Luxiang applied for his resignation as vice president of the company due to personal reasons, and would not hold any position in the company after resignation.
.
On January 4, Mr.
Li Huiliang, deputy general manager, chief technology officer and core technician of Bloomage Bio, resigned from the company's deputy general manager and chief technology officer due to personal reasons, and no longer served as a core technician.
After resigning, he worked in the company and its subsidiaries.
will no longer hold any positions
.
On the same day, Qinhao Pharma announced the official appointment of Dr.
Jie Jack Li () as the company's chief scientific officer (CSO), responsible for the company's global early stage research and development of new drugs
.
On January 3, Boaoxin Bio announced that Dr.
Anthony Yeh will serve as the company's chief strategy officer and head of business development in China, responsible for Boaoxin's corporate strategic planning, business development in China, and financing
.
Before joining Bo Aoxin, Dr.
Ye served as the vice president of CStone Pharmaceuticals and the head of the North Asia Region of Abbott's Business Economics and Strategic Planning Department.
.
.
According to incomplete statistics, since 2022, there have been more than 10 pharmaceutical companies in China.
The pharmaceutical company announced personnel changes
.
In this regard, the industry generally believes that in the context of continuous changes in the pharmaceutical environment, as domestic and foreign pharmaceutical companies continue to adjust their corporate structures and strategic planning, personnel changes among major pharmaceutical companies will become more frequent in the future
.
Tube flow is also significantly accelerated
.
Data shows that in 2021, more than 200 executives in the pharmaceutical industry will leave
.
In the first half of the year alone, a total of 128 executives in the pharmaceutical industry left
.
From the perspective of the overall personnel changes, the positions of vice president, general manager, deputy general manager, secretary of the board of directors, and financial director/director have changed a lot
.
It is worth noting that the current time has come to 2022.
Judging from the current industry trends, the changes of executives in the pharmaceutical industry are still further intensifying.
Recently, many domestic and foreign pharmaceutical companies have announced new changes in executives
.
For example, recently, Dong'e Ejiao has sent two news of personnel changes in a row.
Due to the change of work content, its chairman Han Yuewei and president Gao Dengfeng have resigned one after another
.
Among them, Mr.
Han Yuewei mainly applied for his resignation as chairman and director of the 10th board of directors of the company, and simultaneously resigned as chairman of the strategy committee of the 10th board of directors of the company
.
After resigning, he will no longer hold any positions in the company
.
Mr.
Gao Dengfeng will continue to serve as a director of the tenth board of directors of the company after applying for resignation as the company's president and legal representative
.
Prior to this, biopharmaceutical company Oculis SA also announced the appointment of Ding Weibo as global chief operating officer and general manager of China, effective February 1, 2022, based in Hong Kong, China
.
Before joining Oculis, he was President of Fresenius Kabi China
.
Before joining Fresenius Kabi, Ding Weibo worked at Novartis China for more than 10 years
.
In addition, he has held senior positions at Bristol-Myers Squibb and Xi'an Janssen
.
On January 6, Buchang Pharmaceutical announced that Liu Luxiang applied for his resignation as vice president of the company due to personal reasons, and would not hold any position in the company after resignation.
.
On January 4, Mr.
Li Huiliang, deputy general manager, chief technology officer and core technician of Bloomage Bio, resigned from the company's deputy general manager and chief technology officer due to personal reasons, and no longer served as a core technician.
After resigning, he worked in the company and its subsidiaries.
will no longer hold any positions
.
On the same day, Qinhao Pharma announced the official appointment of Dr.
Jie Jack Li () as the company's chief scientific officer (CSO), responsible for the company's global early stage research and development of new drugs
.
On January 3, Boaoxin Bio announced that Dr.
Anthony Yeh will serve as the company's chief strategy officer and head of business development in China, responsible for Boaoxin's corporate strategic planning, business development in China, and financing
.
Before joining Bo Aoxin, Dr.
Ye served as the vice president of CStone Pharmaceuticals and the head of the North Asia Region of Abbott's Business Economics and Strategic Planning Department.
.
.
According to incomplete statistics, since 2022, there have been more than 10 pharmaceutical companies in China.
The pharmaceutical company announced personnel changes
.
In this regard, the industry generally believes that in the context of continuous changes in the pharmaceutical environment, as domestic and foreign pharmaceutical companies continue to adjust their corporate structures and strategic planning, personnel changes among major pharmaceutical companies will become more frequent in the future
.
